Try our Advanced Search for more refined results

Angioscore, Inc. v. Trireme Medical, Inc. et al

  1. November 17, 2017

    Catheter IP Row Settles After Fed. Circ. Kills $20M Ruling

    AngioScore Inc. and TriReme Medical LLC have settled a breach of duty and patent infringement suit over the design of a heart catheter after the Federal Circuit overturned a $20 million judgment in AngioScore's favor, the companies told a California federal court Thursday.

  2. December 10, 2015

    TriReme Loses $4.7M Fee Bid After Heart Catheter Trial Win

    A California federal judge refused to award TriReme Medical LLC $4.7 million in legal fees after it beat a patent suit from rival AngioScore over a heart catheter design, saying Wednesday that although AngioScore's case wasn't particularly strong, "it wasn't exceptionally weak."

  3. October 28, 2015

    TriReme Takes $20M Catheter IP Loss To Fed. Circ.

    TriReme Medical urged the Federal Circuit Tuesday to consider whether it has to immediately pay a $20 million judgment to rival AngioScore over a heart catheter design, saying a California federal judge's decision not to halt the payout while the appeal proceeds could drive the company into bankruptcy.

  4. October 15, 2015

    TriReme Fears Bankruptcy After $20M Catheter Row Loss

    TriReme Medical urged a California federal judge Wednesday to stay the payout of a $20 million judgment and waive any bond while it appeals its loss in a fight with rival AngioScore over a heart catheter design, saying putting up the money would put it out of business.

  5. September 29, 2015

    TriReme Medical Cleared In Catheter IP Trial, Attys Say

    A California federal jury held that TriReme Medical did not infringe on a patent for a balloon stent claimed by AngioScore, holding that TriReme's vascular stent did not infringe its competitor, attorneys for the parties told Law360 on Tuesday.

  6. September 14, 2015

    Rival Must Pay For Infringing AngioScore Cath IP, Jury Told

    TriReme Medical Inc. should pay five to 10 percent in royalties on sales of its Chocolate balloon catheter, which allegedly infringes AngioScore Inc.'s patent on a device that expands blocked arteries, AngioScore told a California federal jury Monday during opening arguments in its trial against TriReme.